GHRSNASDAQHealthcare · Biotechnology

GH Research PLC

$22.29+1.60%(+$0.35)

TickerSpark Score

57/100

Mixed

Valuation

Profitability

Growth

Health

100

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GHRS research report →

52-Week Range83% of range

Low $10.66

Current $22.29

High $24.66

Companywww.ghres.com

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.

CEO: Velichka Valcheva
IPO: 2021
Employees: 50
HQ: Dublin, IE

Price Chart

+80.18% · this period

Valuation

Market Cap: $1.53B
P/E: -24.51
P/S: 0.00
P/B: 5.25
EV/EBITDA: -22.03
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -19.83%
ROIC: -25.28%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-48,257,999 · -23.86%
EPS: $-0.79 · -5.33%
Op Income: $-60,675,999
FCF YoY: -3.16%

Performance & Tape

52W High: $24.66
52W Low: $10.66
50D MA: $17.62
200D MA: $14.99
Beta: 1.28
Avg Volume: 223.04K

Get TickerSpark's AI analysis on GHRS

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Mar 18, 26	Moore Duncan	director	other	0	—
Mar 18, 26	Moore Duncan	director	other	4,667	$116.675
Mar 18, 26	Cameron Aaron Luke	officer: Chief Operating Officer	other	33,211	$708.06K
Mar 18, 26	Cameron Aaron Luke	officer: Chief Operating Officer	other	100,000	$2.50K
Mar 18, 26	Cameron Aaron Luke	officer: Chief Operating Officer	other	25,000	$145.00K
Mar 18, 26	Hanley Dermot John	director	other	0	—
Mar 18, 26	Hanley Dermot John	director	other	4,667	$116.675
Mar 18, 26	Halle Magnus Clemensen	officer: Managing Director, Ireland	other	0	—
Mar 18, 26	Halle Magnus Clemensen	officer: Managing Director, Ireland	other	50,000	$1.25K
Mar 18, 26	Forer Michael	director	other	0	—

Our GHRS Coverage

View all →

ipo_article

Optimi Health Corp. IPO: What to Know Before It Lists

Optimi Health Corp. (NASDAQ: OPTH) is expected to list on 2026-05-20, with a price range not disclosed and 2,500,000 shares offered. The setup is a small, early commercial psychedelic manufacturer with real revenue, but it is still carrying losses, a working capital deficit, and heavy regulatory dependence.

May 20, 2026